AR069729A1 - Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas - Google Patents

Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas

Info

Publication number
AR069729A1
AR069729A1 ARP080103650A ARP080103650A AR069729A1 AR 069729 A1 AR069729 A1 AR 069729A1 AR P080103650 A ARP080103650 A AR P080103650A AR P080103650 A ARP080103650 A AR P080103650A AR 069729 A1 AR069729 A1 AR 069729A1
Authority
AR
Argentina
Prior art keywords
abeta
treatment
peptide
amino acid
prevention
Prior art date
Application number
ARP080103650A
Other languages
English (en)
Inventor
Hermann Russ
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR069729A1 publication Critical patent/AR069729A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1225—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes using coherent radiation
    • A61B3/1233—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes using coherent radiation for measuring blood flow, e.g. at the retina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10072—Tomographic images
    • G06T2207/10101—Optical tomography; Optical coherence tomography [OCT]
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/20—Special algorithmic details
    • G06T2207/20212—Image combination
    • G06T2207/20224—Image subtraction
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30041—Eye; Retina; Ophthalmic
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T5/00—Image enhancement or restoration
    • G06T5/50—Image enhancement or restoration using two or more images, e.g. averaging or subtraction
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G06T7/0014—Biomedical image inspection using an image reference approach
    • G06T7/0016—Biomedical image inspection using an image reference approach involving temporal comparison
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/30—Determination of transform parameters for the alignment of images, i.e. image registration
    • G06T7/33—Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
    • G06T7/337—Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods involving reference images or patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para la prevencion y el tratamiento de trastornos oculares, en particular glaucoma, a través del bloqueo de los efectos toxicos de derivados de beta-amiloide (Abeta), y composiciones farmacéuticas para efectuar dicha prevencion y su tratamiento. Reivindicacion 1: El uso de un péptido, caracterizado porque comprende la secuencia de aminoácidos X-Y o Y-X, en donde X es un aminoácido aromático e Y es uno o más aminoácidos adicionales distintos de glicina, en donde el péptido tiene al menos 2 residuos de aminoácidos y menos de 15 residuos de aminoácidos, para la fabricacion de un medicamento para la prevencion y el tratamiento de una condicion optica asociada con toxicidad de beta-amiloide (Abeta) en donde se inhibe la formacion y/o aparicion de dicho Abeta. Reivindicacion 3: El uso del péptido de acuerdo con la reivindicacion 1 en combinacion con al menos un agente farmacéutico adicional que es efectivo en el tratamiento de la condicion optica, caracterizado porque la combinacion del péptido de acuerdo con la reivindicacion 1 y el al menos un agente farmacéutico adicional es efectivo para tratar la condicion, Reivindicacion 4: El uso de acuerdo con la reivindicacion 3, caracterizado porque el al menos un agente farmacéutico adicional se selecciona de medicaciones administrados para tratar enfermedades oculares que contienen fármacos antiglaucoma, antibioticos, fármacos antiinflamatorios, esteroides, fármacos antialérgicos y fluido de lágrimas artificiales. Reivindicacion 5: El uso reivindicado de acuerdo con la reivindicacion 3, caracterizado porque el al menos un agente farmacéutico adicional se selecciona de acetazolamida, diclofenamida, carteolol, timolol, metipranolol, betaxolol, pindolol, levobunolol, brimonidina, clonidina, pilocarpina, carbacol, dipivefrina, apraclonidina, brinzolamida, dorzolaminida, bimatoprost, travaprost, latanoprost, clortetraciclina, ciprofloxacina, ofloxacina, ácido fusidínico, gentamicina, canamicina, levofloxacina, lomefloxacina, oxitetraciclina, natamicina, azidamfenicol, cloranfenicol, tobramicina, eritromicina, polimixina-B, aciclovir, trifluridina, betametasona, dexametasona, fluorometolona, hidrocortisona, prednisolona, rimexolona, cromoglicato, azelastina, lodoxamida, emedastina, nedocromilo, levocabastina, olopatadina, ketotifeno, hipromelosa, carbomero, hialuronato, carmelosa, hipromelosa, povidona, hietelosa, alcohol polivinílico, dexpantenol, tetrizolina, troxerutina, tramazolina, nafazolina, xilometazolina, fenilefrina y antazolina. Reivindicacion 8: El uso reivindicado de acuerdo con la reivindicacion 1, caracterizado porque el medicamento es fabricado para proporcionar el péptido en la forma de gotas oculares, cremas oculares y formulaciones intraoculares de deposito. Reivindicacion 12: Una composicion farmacéutica para la prevencion y el tratamiento de una condicion optica asociada con toxicidad de beta-amiloide (Abeta), caracterizada porque la formacion de Abeta y/o la aparicion de dicho Abeta es inhibida al comprender un péptido de acuerdo con la reivindicacion 1, o una de sus sales por adicion de ácido farmacéuticamente aceptable, solo o en combinacion con uno o más portadores y/o excipientes farmacéuticamente aceptables. Reivindicacion 13: Una composicion farmacéutica para la prevencion y el tratamiento de una condicion optica asociada con toxicidad de beta-amiloide (Abeta), caracterizada porque la formacion de Abeta y/o la aparicion de dicho Abeta es inhibida al comprender un péptido de acuerdo con la reivindicacion 3, o una de sus sales por adicion de ácido farmacéuticamente aceptable, solo o en combinacion con uno o más portadores y/o excipientes farmacéuticamente aceptables. Reivindicacion 14: Un péptido que comprende la secuencia de aminoácidos X-Y o Y-X, en donde X es un aminoácido aromático e Y es uno o más aminoácido adicionales distinto de glicina, caracterizado porque el péptido tiene al menos 2 residuos de aminoácidos y menos de 15 residuos de aminoácidos, para la prevencion y el tratamiento de una condicion optica asociada con toxicidad de beta-amiloide (Abeta) en donde a formacion de Abeta y/o la aparicion de dicho Abeta está inhibida.
ARP080103650A 2007-08-21 2008-08-21 Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas AR069729A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96565007P 2007-08-21 2007-08-21
EP07253904A EP2044951A1 (en) 2007-10-02 2007-10-02 The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases

Publications (1)

Publication Number Publication Date
AR069729A1 true AR069729A1 (es) 2010-02-17

Family

ID=39133839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103650A AR069729A1 (es) 2007-08-21 2008-08-21 Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas

Country Status (11)

Country Link
US (3) US20100204137A1 (es)
EP (2) EP2044951A1 (es)
JP (1) JP2010535728A (es)
CN (1) CN101743015A (es)
AR (1) AR069729A1 (es)
AU (1) AU2008290825B2 (es)
CA (1) CA2688215A1 (es)
MX (1) MX2009013604A (es)
RU (1) RU2481120C2 (es)
TW (1) TWI400080B (es)
WO (1) WO2009024346A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
AU2011281837A1 (en) * 2010-07-22 2013-03-14 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition containing a tryptophan derivative
EP2632897B1 (en) 2010-10-29 2014-10-01 Merz Pharma GmbH & Co. KGaA Indole derivatives and process for their preparation
EP2842545B1 (en) * 2012-04-24 2020-02-12 Osaka University Method for producing an aqueous dispersion of drug nanoparticles and use thereof
TW201412325A (zh) 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
US20140161786A1 (en) * 2012-09-04 2014-06-12 Jonathan B. Rothbard Therapeutic compositions and related methods
US10421821B2 (en) * 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
EP3787749A4 (en) * 2018-05-03 2022-01-26 Alimera Sciences, Inc. METHODS OF TREATMENT OF RETINAL DISEASES
JP2022505950A (ja) 2018-10-26 2022-01-14 オキュフィア・ファーマ・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
RU2720453C1 (ru) * 2019-03-28 2020-04-29 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения пациентов с выявленным офтальмогипертензионным синдромом перенапряжения аккомодации
BR112021021267A2 (pt) * 2019-04-24 2021-12-21 Galimedix Therapeutics Inc Compostos de indol para uso na neurorrestauração
RU2726404C1 (ru) * 2020-03-19 2020-07-13 Общество с ограниченной ответственностью "Глазная клиника доктора Беликовой" Способ определения тактики ведения пациентов с латентной стадией закрытоугольной глаукомы и синдромом пигментной дисперсии
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
SE9900473D0 (sv) 1999-02-12 1999-02-12 Karolinska Innovations Ab Inhibitor of endothelial cell proliferation
US7728043B2 (en) * 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20070021345A1 (en) * 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US7345022B2 (en) 2002-09-19 2008-03-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Anti-fibril peptides
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2006517979A (ja) * 2003-02-18 2006-08-03 ロスカンプ リサーチ エルエルシー βセクレターゼインヒビターおよびγセクレターゼインヒビターの抗脈管形成特性および抗腫瘍特性
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
ITMI20041962A1 (it) * 2004-10-15 2005-01-15 Istituto Naz Per La Ricerca S "peptide di angiostatina e suoi impieghio terapeutici"
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2625568C (en) * 2005-10-10 2013-10-08 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
CN101558080A (zh) * 2005-11-10 2009-10-14 罗斯坎普研究有限责任公司 Aβ肽片段对血管生成的调节
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
US20090220463A1 (en) * 2006-01-19 2009-09-03 Doo-Sik Kim Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide
EP1832600A1 (en) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptides against autoantibodies associated with glaucoma and use of these peptides
WO2007109620A2 (en) * 2006-03-17 2007-09-27 San Diego State University Foundation Macrocyclic peptides and methods for making and using them
TW200916091A (en) 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
WO2010040232A1 (en) 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US20110200531A1 (en) 2009-09-14 2011-08-18 The Regents Of The University Of California Treatment and diagnosis of central nervous system disorders
TWI486162B (zh) * 2010-06-16 2015-06-01 Sinphar Pharmaceutical Co Ltd 異類葉升麻苷或其醫藥學上可接受之鹽於抑制澱粉樣β肽生成、累積或聚集、以及製備預防或治療澱粉樣β肽相關疾病或狀況的藥物之用途
EP2632897B1 (en) 2010-10-29 2014-10-01 Merz Pharma GmbH & Co. KGaA Indole derivatives and process for their preparation
EP2640737B1 (en) 2010-11-15 2018-08-29 Ramot at Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
TW201412325A (zh) * 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療

Also Published As

Publication number Publication date
JP2010535728A (ja) 2010-11-25
AU2008290825A1 (en) 2009-02-26
MX2009013604A (es) 2010-01-26
WO2009024346A2 (en) 2009-02-26
RU2481120C2 (ru) 2013-05-10
TWI400080B (zh) 2013-07-01
EP2044951A1 (en) 2009-04-08
CN101743015A (zh) 2010-06-16
CA2688215A1 (en) 2009-02-26
US20200085906A1 (en) 2020-03-19
WO2009024346A3 (en) 2009-06-04
US10987400B2 (en) 2021-04-27
US20170065664A1 (en) 2017-03-09
TW200916112A (en) 2009-04-16
US10525097B2 (en) 2020-01-07
US20100204137A1 (en) 2010-08-12
AU2008290825B2 (en) 2012-07-12
RU2010110544A (ru) 2011-09-27
EP2180898A2 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
AR069729A1 (es) Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas
JP6419876B2 (ja) 眼科治療
CN113679698B (zh) 包含半氟化烷烃的混合物的组合物
HRP20231277T1 (hr) Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije
KR20190060787A (ko) 카나비노이드 수용체 결합 리간드를 포함하는 조성물
JP2013502460A5 (es)
JP2014513073A5 (es)
JP2009501726A (ja) 眼科学的活性剤の製剤とその投与の方法
EP1904108A2 (en) Formulation and method for administration of ophthalmologically active agents
Henderer et al. Ocular pharmacology
ES2751248T3 (es) Agente protector queratoconjuntival o agente inhibidor de trastornos queratoconjuntivales
JP7355539B2 (ja) 眼科組成物
JP2013508383A (ja) 瞳孔拡張を調節するための、フェントラミンを含む組成物及び方法
JP2024079810A (ja) キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤
JP5147156B2 (ja) 角膜障害抑制剤
JP2023093761A (ja) 異物感改善用眼科組成物
BR112021005097A2 (pt) lágrima artificial, lentes de contato e composições de veículos medicinais e métodos de uso dos mesmos
TW201936173A (zh) 兩性離子性軟式隱形眼鏡用眼科用組成物
JP5499535B2 (ja) 眼科用組成物及びなみだ目改善剤
US20230285286A1 (en) Drug vehicle compositions and methods of use thereof
WO2015029925A1 (ja) 網膜疾患の予防、改善、又は治療剤
JP2010189442A (ja) 角膜障害抑制剤

Legal Events

Date Code Title Description
FB Suspension of granting procedure